ENABLE-2 INCUBATOR HIT TO LEAD PROGRAMME

expression of interest template

(3 pages maximum)

ENABLE-2 is supporting the development of direct acting antibacterial compounds for systemic use. Potentiator molecules may also be in scope, e.g. β-lactamase inhibitors. Anti-virulence and anti-biofilm compounds are not in scope.

**Applicants must enter a response to each question below.**

**Where data is not available, state whether the work has not yet been undertaken.**

Please include non-confidential data only.

The completed EoI should be returned to [opencall.enable2@ilk.uu.se](mailto:opencall.enable2@ilk.uu.se) and if you have any questions regarding the completion of the EoI you can use the same email address.

# Questions

**Question 1:** Name and address of legal entity.  
Full contact details of primary person submitting this EoI.  
If your legal entity is a university or research institute, is it publicly funded?

**Question 2a:** Confirmation that the applicant has direct ownership or permission to develop the programme.

**Question 2b:** Have similar compounds previously been under development? Are there existing publications and/or patents on these compounds or similar compounds? Please describe how this affects your programme.

**Question 3:** Short history of the programme (max 200 words).

**Question 4:** MIC vs one or more ENABLE-2 key pathogens (*E. coli*, *K. pneumoniae*, *P. aeruginosa*, *A. baumannii*, *S. aureus*, *E. faecium*). MIC ≤16 μg/ml on wild-type bacteria is threshold for hit entry (indicate method used to measure MIC).

**Question 5:** Frequency of resistance.

**Question 6:** Data to support specific mode of action (not detergent-like activity).

**Question 7:** Cytotox data.

**Question 8:** Indicate novelty of structure and if SAR is established.

**Question 9:** Synthetic feasibility. Number of steps in synthesis pathway.

**Question 10:** Availability of compound for immediate evaluation.

**Question 11:** Physchem parameters, mw, logP and solubility etc.